Skip to main content
PLOS One logoLink to PLOS One
. 2023 Jun 22;18(6):e0287558. doi: 10.1371/journal.pone.0287558

Characterization of the biochemical activity and tumor-promoting role of the dual protein methyltransferase METL-13/METTL13 in Caenorhabditis elegans

Melanie L Engelfriet 1, Jędrzej M Małecki 1, Anna F Forsberg 1, Pål Ø Falnes 1,*, Rafal Ciosk 1,*
Editor: Alexander F Palazzo2
PMCID: PMC10286969  PMID: 37347777

Abstract

The methyltransferase-like protein 13 (METTL13) methylates the eukaryotic elongation factor 1 alpha (eEF1A) on two locations: the N-terminal amino group and lysine 55. The absence of this methylation leads to reduced protein synthesis and cell proliferation in human cancer cells. Previous studies showed that METTL13 is dispensable in non-transformed cells, making it potentially interesting for cancer therapy. However, METTL13 has not been examined yet in whole animals. Here, we used the nematode Caenorhabditis elegans as a simple model to assess the functions of METTL13. Using methyltransferase assays and mass spectrometry, we show that the C. elegans METTL13 (METL-13) methylates eEF1A (EEF-1A) in the same way as the human protein. Crucially, the cancer-promoting role of METL-13 is also conserved and depends on the methylation of EEF-1A, like in human cells. At the same time, METL-13 appears dispensable for animal growth, development, and stress responses. This makes C. elegans a convenient whole-animal model for studying METL13-dependent carcinogenesis without the complications of interfering with essential wild-type functions.

Introduction

Protein methylation is a prevalent type of post-translational modification (PTM). It modulates the activity, cellular location, and interactions of proteins. Protein methyltransferases (MTases) are enzymes that catalyze the transfer of a methyl group from the donor S-adenosylmethionine (AdoMet) to a target amino acid residue [1]. The human methyltransferasome contains 208 known or putative MTases, of which most fall in either the seven-β-strand (7BS) family (60% of MTases) or the Su(var)3-9, Enhancer-of-zeste, Trithorax (SET) family (27% of MTases) [2]. Methylation occurs most often on lysines and arginines, but other residues, such as histidines and the N- and C-termini of proteins, are also methylated [312]. Lysine residues can receive up to three methyl groups on the ε-nitrogen of the lysine side chain, resulting in their mono-, di-, or trimethylation (referred to here as me1, me2, and me3, respectively). Although lysine methylation of histone proteins has received much attention, many lysine-specific MTases (KMTs) methylate non-histone proteins [4, 9].

The translation of mRNA into protein, which depends on a number of conserved translation factors, consists of three steps: initiation, elongation, and termination [13]. The eukaryotic elongation factor 1 alpha (eEF1A) functions during translation elongation to deliver an aminoacyl-tRNA to the A-site of the translating ribosome as an aminoacyl-tRNA-eEF1A-GTP complex. Complementary tRNA-mRNA codon recognition stimulates eEF1A to hydrolyze GTP and causes eEF1A-GDP to exit the complex.

Mammalian eEF1A contains multiple reported PTMs, of which phosphorylation and methylation have been accredited to influencing its activity in translation to various degrees. Phosphorylation of multiple residues on eEF1A by different kinases stimulates the overall protein translation, with the exception of phosphorylated S300, which blocks aminoacyl-tRNA binding [1417]. The methylation landscape of human eEF1A includes five methylated lysine residues and the methylated N-terminus [18]. Although little is known about the methylation status of the eEF1A N-terminus in relation to its function, methylation of the different lysine residues seems to modulate translation rates of different codons or proteins involved in various cellular processes [18]. The KMTs responsible for methylating human eEF1A at the various lysine residues were identified, with eEF1A-KMT4 (ECE2), eEF1A-KMT1 (N6AMT2), eEF1A-KMT3 (METTL21B), and eEF1A-KMT2 (METTL10) being responsible for methylating K36, K79, K165, and K318, respectively [1923]. The newest player here is the methyltransferase-like protein 13 (METTL13). Its sole substrate appears to be the translation factor eEF1A [24, 25]. METTL13 is a dual 7BS MTase, containing an N-terminal KMT domain which mediates dimethylation of K55 and a C-terminal MTase domain which, after removal of the initiator methionine by methionine aminopeptidases, trimethylates the N-terminal amino group of G2 [24, 25]. The methylation marks deposited by METTL13 seem to fine-tune the activity of eEF1A in translation [24].

METTL13 and dimethylated K55 on eEF1A are abundant in many human cancers, which correlates with poor patient prognosis [2528]. Recent studies have strengthened the cancer connection, as proliferation and global protein synthesis are impaired in transformed cells depleted of METTL13 [25, 26]. Furthermore, the loss of METTL13 function in xenograft mouse models, and depletion of pancreatic METTL13 in a mouse model of Ras-driven pancreatic duct adenocarcinoma (PDAC), were shown to suppress tumor growth [25, 26]. However, it is not clear what roles, if any, METTL13 plays in wild-type animals. Here, we examined the possible functions of METTL13 in a whole animal, the nematode C. elegans. Combining biochemical and genetic approaches, we show that the C. elegans METTL13, METL-13, methylates the nematode eEF1A, EEF-1A, at the same positions as the human protein. Examining animals lacking METL-13 or its methylations of EEF-1A, we observed no evident defects in animal growth and development. However, we found that the METL-13-dependent methylation of EEF-1A promotes C. elegans tumorigenesis. We conclude that METTL13 has a conserved biochemical function from humans to nematodes. Remarkably, METL-13/METTL13 and its methylation of EEF-1A/eEF1A appear to be dispensable for animals under laboratory culture conditions. Thus, assuming the conservation, targeting METTL13 in cancer therapy could bypass the toxicity associated with targeting essential proteins.

Results

C. elegans METL-13 is a dual-specificity methyltransferase targeting the G2 and K55 residues of EEF-1A

The C. elegans ortholog of the human METTL13 gene is C01B10.8, henceforth metl-13. The human METTL13 and nematode METL-13 proteins are highly similar: 33% of their amino acid sequence is identical and they share similar domain arrangement, with two 7BS MTase-like domains separated by a linker region (Fig 1A). The N-terminal KMT domain of METTL13 dimethylates eEF1A at K55 (eEF1AK55me2), whereas the C-terminal KMT domain trimethylates the amino group of G2 (eEF1AG2me3) [24] (Fig 1A and 1B).

Fig 1. The domain organization of METTL13 is conserved in C. elegans.

Fig 1

A. Overview of the domain organization of human METTL13 and C. elegans METL-13. The boundaries of MTase domains (MT13-C and MT13-N), used in the in vitro methyltransferase assays, are indicated by amino acid positions. B. Architecture of the human eEF1A protein and its methylations. Arrows point to residues methylated by the indicated MTases, with METTL13 and its targeted residues in bold. Red spheres indicate methyl groups.

To find out if nematode METL-13 has similar enzymatic activities as its human counterpart, we expressed and purified from E. coli two N-terminally hexahistidine (His6) tagged fragments of METL-13 encompassing its individual MTase domains (Fig 1A). These METL-13 fragments were tested in an in vitro assay to monitor their putative MTase activities, using recombinant human (Hs) eEF1A as the protein substrate and [3H]-AdoMet, as methyl donor, allowing the detection of [3H]-methylated eEF1A by fluorography as a distinct band on SDS-PAGE. We decided to use the recombinant Hs eEF1A as the substrate based on its high homology to the nematode ortholog and nearly identical sequence surrounding the putative METL-13 target sites (S1A Fig in S1 File). We observed that the C-terminal domain of METL-13 could methylate eEF1A bearing a C-terminal His-tag, but not when the His-tag was present on the N-terminus, suggesting that the methylation occurs at the N-terminus of eEF1A (Fig 2A). Indeed, mutating G2 to I (G2I) abolished the methylation of eEF1A, whereas mutating K55 to R (K55R) had little effect (Fig 2A). In contrast, the N-terminal domain of METL-13 methylated Hs eEF1A, regardless of the position of the His-tag or the G2I substitution (Fig 2B). Most importantly, the methylation was abolished by the K55R substitution, pointing to K55 of eEF1A as the key methylation site (Fig 2B). These experiments show that the enzymatic activities of individual domains of METL-13 match the established activities of human METTL13, i.e., its N-terminal domain targets K55, whereas the C-terminal domain targets G2 of eEF1A.

Fig 2. The biochemical function of METTL13 is conserved in C. elegans.

Fig 2

A,B. Evaluation of the methyltransferase activity of the C. elegans METL-13 fragments, using recombinant human eEF1A1 as the substrate. The MT13-C (A) and MT13-N (B) fragments were incubated with [3H]-AdoMet and human eEF1A1 variants as indicated; His-tagged at either the N- or C-terminus and in some cases with point substitutions (G2I or K55R). Methylation was visualized by fluorography (top panels). Protein loading was assessed by Ponceau S staining (bottom panels). C. RT-qPCR analysis of metl-13 mRNA levels in wild-type (wt) and metl-13(tm6870) animals. The levels of metl-13 were assessed using primers spanning the exon 2–3 junction and normalized to the levels of act-1 (actin) mRNA. Error bar indicates SEM from 3 biological replicates; ***: p<0.001. D,E. Quantitative analysis of the endogenous methylation of EEF-1A, on G2 (D) and K55 (E) in the extracts from wt or metl-13(tm6870) animals, using LC-MS/MS; n.d.: not detected.

To demonstrate that METL-13 functions as a MTase in vivo, we used a previously uncharacterized mutant strain, carrying a homozygous deletion in the metl-13 locus. This mutation, metl-13(tm6870), causes a frameshift at the end of exon 3, leading to a premature stop codon (S1B Fig in S1 File). Nonsense-mediated mRNA decay (NMD) is expected to degrade the resulting mRNA and, indeed, the levels of metl-13 mRNA were significantly lower in the metl-13(tm6870) strain than in wild-type (wt) (Fig 2C). Moreover, any residual METL-13 protein would lack part of the N-terminal MTase domain and the whole C-terminal MTase domain. Thus, metl-13(tm6870) animals should express no functional METL-13 protein. To confirm that the metl-13(tm6870) strain is devoid of METL-13 activity, we analyzed the methylation status of G2 and K55 of the endogenous EEF-1A/eEF1A in metl-13(tm6890) and wild-type animals. Using liquid chromatography-tandem mass spectrometry (LC-MS/MS), we found that G2 on EEF-1A was fully trimethylated and K55 was virtually fully (99.6%) dimethylated in wild-type animals (Fig 2D and 2E). In contrast, both residues were completely unmethylated in metl-13(tm6870) mutants (Fig 2D and 2E). Thus, METL-13 is responsible for the G2 and K55 methylation of EEF-1A in vivo.

Next, since the main target of METTL13 is eEF1A, we examined the potential impact of METL-13-mediated methylation on EEF-1A. Firstly, we examined the levels of EEF-1A by western blotting but observed no difference in its levels between metl-13(tm6870) mutants and wild-type animals (Fig 3A). Secondly, we used CRISPR-Cas9 engineering to create the K55R substitution in EEF-1A. Since the highly similar genes eef-1A.1 and eef-1A.2 (94% identical covering 1392 bases, including a stop codon) encode the fully identical EEF-1A protein, we first created the eef-1A.1(syb2837) and eef-1A.2(syb2785) single mutants, each encoding EEF-1A containing a K55R mutation. These two mutants were then crossed to obtain the eef-1A.1(syb2837); eef-1A.2(syb2785) double mutant. Analyzing this strain, we observed no difference between the levels of wild-type and K55R EEF-1A (Fig 3A).

Fig 3. Ablation of METL-13 or EEF-1AK55me2 does not affect protein levels of EEF-1A or protein synthesis.

Fig 3

A. Protein levels of the C. elegans eEF1A, EEF-1A, do not change upon the loss of METL-13. Left: western blot showing the levels of EEF-1A and actin (loading control) in whole lysates from mixed-staged wt, metl-13(tm6870), and eef-1A.1(syb2837); eef-1A.2(syb2785) mutant animals. Right: Densiometric quantification of EEF-1A levels, normalized to actin. Error bars indicate SEM of 3 biological replicates; n.s.: not significant. B. Quantification of puromycin incorporation in the lysates from wt and metl-13(tm6870) mutants. The levels of incorporated puromycin were normalized to the levels of β-actin used as a loading control. Error bars indicate SEM of 3 biological replicates; n.s.: not significant.

Finally, using surface sensing of translation (SUnSET) [29, 30], we asked whether the loss of METL-13 impacts global protein synthesis. However, we observed no obvious difference between the wild type and metl-13(tm6870) mutants (Fig 3B). Concluding, the biochemical activity of C. elegans METL-13 and human METTL13 is conserved. METTL13/METL-13 targets eEF1A/EEF-1A at two independent sites, introducing dimethylation at K55 and trimethylation at G2. However, at standard growth conditions, these modifications appear to have no obvious impact on global translation.

The K55 methylation of EEF-1A increases the penetrance of germline tumors

In humans, increased levels of METTL13 and eEF1AK55me2 correlate with poor survival of patients with lung or pancreatic cancer [25]. Furthermore, the ablation of METTL13 reduces proliferation and global protein synthesis in cancer cells, while non-transformed cells appear unaffected [25, 26]. Since the biochemical function of METL-13 is conserved in C. elegans, we tested whether it also plays a role in tumorigenesis. Many C. elegans factors function as germline tumor suppressors [31]. Among them is GLD-1, a maxi-KH/STAR RNA-binding protein functioning as a translational repressor [3235]. Another example is PRO-1, a conserved WD-repeat protein implicated in rRNA processing [36]. Without these factors, germ cells develop into highly penetrant tumors, although found in different gonadal regions (Fig 4A).

Fig 4. Depletion of METL-13 reduces the severity of germline tumors.

Fig 4

A. Diagrams of wild-type and tumorous C. elegans germlines, tumorous cells are marked in red. While the gonads of gld-1(q485) mutants display large proximal germline tumors, the gonads of pro-1(na48) mutants grown at the restrictive temperature (25°C) contain smaller tumors located proximal to the gametes. B. DIC micrographs of adult wt animals subjected to gld-1 RNAi. The gonads are outlined. Three phenotypes were observed after gld-1 RNAi, we refer to these gonads as ‘fully proliferative’, ‘proliferative with enlarged cells’ (black arrowheads indicate enlarged cells), and ‘wt-like’ respectively. Scale bar = 20 μm. Quantification of the germline phenotypes observed after gld-1 RNAi in wt, metl-13(tm6870), and eef-1A.1(syb2837); eef-1A.2(syb2785) animals show that the predominant phenotype is ‘fully proliferative’ in wt and ‘proliferative with enlarged cells’ in metl-13(tm6870) and eef-1A.1(syb2837; eef-1A.2(syb2785) animals. The quantification shows the average phenotype distribution from three biological replicates, 70 germlines were assessed per biological replicate. C. DIC micrographs of pro-1(na48) mutants (grown at the restrictive temperature, 25°C). The gonads are outlined. Three phenotypes were observed: we refer to seemingly normal germlines as ‘wt-like’, germlines containing proliferating cells proximal to the gametes as ‘proximal tumor’ (indicated by a white arrow), and germlines lacking a proximal tumor that instead contain abnormal oocytes as ‘abnormal oocytes’ (indicated by black arrowheads). Scale bar = 20 μm. Quantification of the germline phenotypes observed after mock or metl-13 RNAi show a decrease in the ‘proximal tumor’ phenotype and an increase in the ‘abnormal oocytes’ and ‘wt-like’ phenotypes when metl-13 is knocked-down. The quantification shows the average phenotype distribution from three biological replicates, 70 germlines were assessed per biological replicate.

Therefore, to evaluate the role of METL-13 in tumorigenesis, we knocked down gld-1 by RNAi in either wild-type animals or metl-13(tm6870) mutants. Upon depletion of GLD-1, germ cells that have entered meiosis revert to the mitotic cycle, resulting in an ectopic mass of proliferative cells that we refer to as a ‘fully proliferative’ phenotype. In the wild type, most gonads displayed large tumors in the proximal/medial regions, as expected; these tumors consisted of small, undifferentiated cells (Fig 4B). In the metl-13(tm6870) mutants, however, many of the tumorous gonads contained enlarged cells reminiscent of differentiating oocytes, we refer to this gonad phenotype as ‘proliferative with enlarged cells’ (Fig 4B and S2A Fig in S1 File). Importantly, we observed a similar increase in the differentiating cells in the eef-1A.1(syb2837); eef-1A.2(syb2785) double mutants (Fig 4B and S2A Fig in S1 File). These differences were not caused by less efficient RNAi in the absence of METL-13-mediated methylation, as RNAi against another target was as efficient in the metl-13(tm6870) or eef-1A.1(syb2837); eef-1A.2(syb2785) mutants as in the wild-type (S3A Fig in S1 File). These results suggest that the tumors are less penetrant without the K55 methylation of EEF-1A. To confirm this finding in another tumorous background, we RNAi-depleted metl-13 in temperature-sensitive pro-1(na48) mutants. At the restrictive temperature (25°C), most of the pro-1(na48) gonads displayed proximal tumors, while a minority looked superficially wild-type or contained abnormal oocytes (Fig 4C). However, the numbers of gonads with proximal tumors significantly decreased upon metl-13 RNAi, and the fraction of wt-like gonads/gonads containing abnormal oocytes increased (Fig 4C and S2B Fig in S1 File). Concluding, our results suggest that METL-13-mediated methylation of EEF-1A enhances tumorigenesis in the nematodes, which is reminiscent of the tumor-promoting role of human METTL13.

METL-13 is non-essential for animal growth and development

To analyze the potential function of METL-13 in wild-type animals, we singled synchronized L4 wild-type or metl-13(tm6870) animals to individual plates, allowed them to grow, and counted their offspring. Since the speed of C. elegans development and the offspring size depend on temperature [37], these experiments were performed at 15°C, 20°C, and 25°C (Fig 5A). At all tested temperatures, we observed no difference in the offspring or developmental speed between the wild-type and mutant animals (Fig 5B).

Fig 5. The loss of METL-13 has no obvious impact on the C. elegans growth under standard culture conditions or nutrient-rich diet.

Fig 5

A. Schematic representation of the development and fecundity assays shown in B. Synchronized wt and metl-13(tm6870) animals were grown to the L4 stage at 20°C, after which they were singled to individual plates and grown at indicated temperatures. Their offspring were counted when reaching the L4 stage (red arrows) and removed from the plate. B. Left: The L4 offspring of singled animals were counted each day at the indicated temperatures. Note that they developed into L4s with a similar speed as wild type. Error bars indicate SEM from 3 biological replicates. Right: Total L4 offspring per animal at the indicated temperatures. Error bars indicate SEM from 3 biological replicates. C. Body area measurements of 1-day old adult wt and metl-13(tm6870) animals grown at 25°C on a diet of OP50 or HB101 bacteria. Error bars indicate SEM of 3 biological replicates, the body area of a minimum of 15 worms was measured per biological replicate. D. Developmental time of wt and metl-13(tm6870) nematodes grown from an egg until an egg-laying adult at 25°C, on a diet of OP50 or HB101 bacteria. Error bars indicate SEM of 3 biological replicates, developmental egg-to-egg time was measured for 20 worms per biological replicate.

Since tumorigenesis is linked to increased protein synthesis, we also examined animals cultivated on bacterial diet enhancing growth and development. In contrast to a standard diet of the E. coli OP50 strain, animals fed the E. coli HB101 strain develop faster and grow larger [3841]. This is due to an increased cell size rather than cell number and reflects the increased protein content of HB101-fed animals [40]. To further accelerate growth and thus the demand for protein synthesis, the animals were cultured at 25°C [37]. As anticipated, wild-type animals that were fed HB101 bacteria developed faster and grew bigger. However, there was no difference between the wild-type and metl-13(tm6870) mutants (Fig 5C and 5D). Thus METL-13 appears dispensable for wild-type growth and development, even under conditions requiring increased protein synthesis.

Finally, when comparing the lifespan of animals with or without functional METL-13, we noticed a small but significant difference, with the metl-13(tm6870) mutants dying a little faster than the wild-type (Fig 6). However, the lifespan of eef-1A.1(syb2837); eef-1A.2(syb2785) double mutants was not different from the wild-type (Fig 6), suggesting that the longevity-related role of METL-13 is unrelated to the K55 methylation of EEF-1A.

Fig 6. The absence of METL-13 impacts lifespan independently of the EEF-1A K55 methylation.

Fig 6

Lifespan assay performed at 20°C, in 3 biological replicates (>100 animals per strain, per replicate). P-value wt vs. metl-13(tm6870): 0.024; p-value wt vs. eef-1A.1(K55R); eef-1A.2(K55R): 0.43, log-rank test.

Discussion

Here, we have studied the previously uncharacterized C. elegans orthologue METL-13. The biochemical function of METL-13 is remarkably conserved, with the dual methyltransferase being responsible for the same methylation marks in vivo on the nematode EEF-1A/eEF1A as in humans.

There is much interest in METTL13 due to its apparent role in cancer. METTL13 and eEF1AK55me2 are upregulated in a plethora of human cancers [2528]. Moreover, targeting METTL13 or the downstream eEF1AK55 inhibits neoplastic growth in human cell lines, as well as in xenograft and PDAC mouse models [25, 26]. Remarkably, the depletion of METL-13 has a similar inhibitory effect on the C. elegans tumors, as the severity of genetically induced germline tumors declined in the absence of METL-13 or EEF-1AK55me2. We note that inhibiting METL-13 or EEF-1AK55me2 did not suppress tumors completely. Also, the partial suppression was no longer observed when we used the gld-1(q485) null mutants instead of gld-1 RNAi (S3B Fig in S1 File). Thus, the loss of EEF-1AK55me2 reduces but does not abolish cancer, at least in the tested tumorous genetic backgrounds.

So how does eEF1AK55me2 impact cancer? The methylation of K55 upregulates the GTPase activity of eEF1A, which may cause increased protein synthesis needed for tumorigenic growth [25]. The elongation factor eEF1A is known to be present in excess compared to other components of the translation machinery. This suggests that eEF1A is unlikely to be rate-limiting in protein synthesis and that its non-canonical functions might instead play a role in cancer [42, 43]. Alternatively, translation capacity may be in surplus under normal conditions but becomes limiting in cancer. This is consistent with the finding that eIF4E haploinsufficient mice develop normally, with wild-type levels of protein synthesis, but are more resistant to oncogenic transformation [44]. While the etiology of human and C. elegans tumors is likely different, it is intriguing that mutating various C. elegans RNA-binding proteins, which like GLD-1 function to repress translation, leads to germline tumors [31]. Thus, reducing translational output, by removing METL-13, could explain the partial suppression of the tumorous proliferation observed upon the depletion of GLD-1. Whether the same applies to pro-1 tumors is less clear, as their etiology is less well understood [36].

Cancer treatments typically involve the inhibition of essential proteins like cell cycle regulators and signaling molecules. This is why chemotherapy often causes serious adverse effects in cancer patients [4547]. The METTL13-mediated methylation of eEF1A could be inhibited by small molecules. However, METTL13 knock-outs have thus far only been studied in cell lines and specific tissues [25, 26]. Our whole-animal study suggests that a complete removal of METL-13 or EEF1-AK55me2 has no obvious impact on wild-type growth and development. This does not preclude potential functions under specific conditions or contexts. Curiously, METL-13 appears to play a limited but significant role in longevity. However, animals in which EEF-1A is no longer methylated on K55 do not display this longevity defect. Thus, this effect could depend on METTL13-mediated methylation of the G2 residue on EEF-1A, the methylation of another substrate, or an additional function of METTL13. In summary, our studies establish a simple model for METL-13-assisted tumorigenesis and endorse the eEF1AK55 modification as an attractive target in cancer therapy, whose inhibition could help reduce cancer growth without the side effects associated with traditional drugs used in chemotherapy.

Methods

C. elegans culture and generation of mutant strains

Animals were maintained using standard procedures and grown at 20°C unless stated otherwise [41]. Information on the strains used in this study are reported in Table 1. The metl-13(tm6870) strain was outcrossed thrice with wild-type males to reduce background mutations. The eef-1A.1(syb2837) and eef-1A.2(syb2785) strains were generated by SunyBiotech using CRISPR-Cas9 technology and outcrossed thrice with wild-type males before crossing them together to generate the double mutant, which was again outcrossed three-times with wild-type males to reduce background mutations. To synchronize animals, embryos were extracted from gravid adults by treatment with a bleaching solution (30% (v/v) sodium hypochlorite (5% chlorine) reagent (ThermoFisher Scientific; 419550010), 750 mM KOH). The embryos were left to hatch overnight into arrested L1 larvae in the absence of food, at RT in M9 buffer (42 mM Na2HPO4, 22 mM KH2PO4, 86 mM NaCl, 1 mM MgSO4). For RNAi experiments, synchronized L1s were grown at 25°C to adults on RNAi-inducing NGM agar plates seeded with HT115 E. coli bacteria containing plasmids targeting genes of interest [48].

Table 1. Strains used in this study.

Strain genotype Source Identifier
Wild type CGC N2
metl-13(tm6870) (IV) NBRP RAF2267
eef-1A.1(syb2837) (III); eef-1A.2(syb2785) (X) This study RAF2260
pro-1(na48)/mIn1[dpy-10(e128) mIs14] (II) CGC GC565
metl-13(tm6870) (IV); lin-41(rrr3) (I); xeSi197[Plin-41::flag::gfp::lin-41::lin-41 3’UTR; unc-119(+)] (II) This study RAF2265
eef-1A.1(syb2837) (III); eef-1A.1(syb2785) (X); lin-41(rrr3) (I); xeSi197[Plin-41::flag::gfp::lin-41::lin-41 3’UTR; unc-119(+)] (II) This study RAF2266

Cloning of METL-13

The ORFs encoding fragments of METL-13 protein (MT13-N: amino acids 1–417; MT13-C: amino acids 213–656), were amplified by PCR from C. elegans cDNA and cloned between NdeI and NotI sites into pET28a plasmid (Novagen), using In-Fusion® HD Cloning Plus kit (Takara). The cloning primers are listed in Table 2. Sanger sequencing was used to verify all cloned constructs.

Table 2. Cloning primers used in this study.

Name Sequence (5’→ 3’)
MT13N-NdeI-F CGCGGCAGCCATATGTCCGCTCCAAATGAGC
MT13N-NotI-R CTCGAGTGCGGCCGCTTATTTCAGATAAGCTTCAGATTGTAC
MT13C-NdeI-F CGCGGCAGCCATATGCCTCTAGAAGTTCTTCGCTCC
MT13C-NotI-R CTCGAGTGCGGCCGCTTAATAATCAACCATACGAATGTTTGAG

Expression and purification of recombinant proteins

Expression and purification of recombinant N-terminally His6-tagged C. elegans MT13-N and MT13-C proteins from E. coli was performed using Ni-NTA-agarose (Qiagen), following a previously described protocol [49]. Cloning, mutagenesis and purification of recombinant human eEF1A1, containing either N-terminal or C-terminal His6-tag, was described previously [21, 24]. Protein concentration was determined using Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Recombinant proteins were stored in Storage Buffer (50 mM Tris-HCl pH 7.4, 100 mM NaCl, 10% glycerol) in single use aliquots, kept at −20°C.

In vitro methyltransferase assay using [3H]AdoMet

MTase activity assay using C. elegans MT13-N or MT13-C as enzymes, human eEF1A1 as the substrate and [3H]AdoMet (PerkinElmer) as the methyl donor, was performed similarly as previously described [24]. 10 μl reactions were set-up on ice in Storage Buffer, containing 1 μg of eEF1A1, 1 μg of MT13-N or MT13-C and 0.5 μCi of [3H]AdoMet. Reaction mixtures were incubated for 1 h at 30°C and analyzed by SDS-PAGE. Proteins were transferred to polyvinylidene difluoride membrane and stained with Ponceau S. Incorporation of tritium-labeled methyl groups into proteins was visualized by fluorography. All methyltransferase experiments were independently replicated at least two times.

RNA extraction

Pellets of 100 μl containing a mix of embryos, larvae and adults were prepared by harvesting the animals (grown on NGM agar plates with OP50 bacteria), adding 250 μl Trizol and snap-freezing in liquid nitrogen. Animals were lysed by 10 freeze-thaw cycles with liquid nitrogen and incubating at 37°C respectively. Chloroform extraction was used by adding 50 μl chloroform and centrifugation at 12000 x g for 10 minutes. The aqueous phase was transferred into new microcentrifuge tubes and 1 volume of isopropanol was added and mixed well. The samples were centrifugated at 16100 x g for 20 minutes at 4°C, after which the RNA pellet was washed with 80% ethanol and air-dried before being resuspended in nuclease-free water. The quality of the RNA was assessed using NanoDrop Spectrophotometer.

RT-qPCR

The QuantiTect Reverse Transcription Kit (Qiagen) was used for elimination of genomic DNA and reverse transcription using 1 microgram of RNA. The cDNA was diluted 1:5 and 2.5 μl of this dilution was used with 2 μl HOT FIREPol EvaGreen qPCR Mix (Solis BioDyne, 08-36-00001) and 0.25 μl of 10 μM gene-specific forward and reverse primers for metl-13 (forward: CGGAATTAGCGACCCAACTCT; reverse: TCGGCCATGGATAGATTAGCA) or act-1 (forward: TTGCCCCATCAACCATGAAGA; reverse: TGTGCAAGTTGACGAAGTTGTG).

Enrichment of EEF-1A from nematode extracts

Pellets containing a mix of embryos, larvae and adults were prepared by collecting the animals (grown on NGM agar plates with E. coli OP50 bacteria) in M9 buffer and washing thrice before removing all of the buffer and snap-freezing in liquid nitrogen. Extracts were prepared by grinding the pellet with a mortar and pestle in the presence of liquid nitrogen and dissolving in Lysis Buffer (50 mM Tris-HCl pH 7.4, 100 mM NaCl, 1% Triton X-100, 5% glycerol (w/vol), 5 mg/ml cOmplete Proteinase Inhibitor Tablets (Roche, 11697498001), 1% P8340 (Sigma)). Extracts were cleared by centrifugation at 16100 x g for 5 minutes at 4°C. EEF-1A protein was enriched from the C. elegans extracts using a method previously employed for enrichment of eEF1A1 present in human cell extracts [21]. Extracts were loaded on Pierce Strong Cation Exchange (S) Spin Columns (Thermo Fisher Scientific, 90008) pre-equilibrated in Lysis Buffer, followed by extensive washing of the columns with Washing Buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 5% glycerol (w/vol), 5 mg/ml cOmplete Proteinase Inhibitor Tablets (Roche, 11697498001), 1% P8340 (Sigma)). The retained material, including EEF-1A, was eluted from the columns with Elution Buffer (50 mM Tris-HCl pH 7.4, 400 mM NaCl, 5% glycerol (w/vol), 5 mg/ml cOmplete Proteinase Inhibitor Tablets (Roche, 11697498001), 1% P8340 (Sigma)).

Mass spectrometry

Mass spectrometry analysis was essentially performed as previously described [24]. In brief, protein samples enriched for EEF-1A (obtained as described above) were resolved by SDS-PAGE and stained with Coomassie Blue. A band corresponding to the mass of EEF-1A (~ 50 kDa) was excised from the gel and subjected to in-gel digestion using chymotrypsin or Glu-C, after which the resulting proteolytic fragments were desalted using 10 μl OMIX C18 micro-SPE pipette tips (Agilent, Santa Clara, CA, USA). The samples were analyzed by nanoLC-MS using either an Ultimate 3000 RSLCnano-UHPLC system connected to a Q Exactive mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) or a NanoElute-UHPLC coupled to a TimsTOF Pro mass spectrometer (Bruker Daltonics, Bremen, Germany). The LC-MS data were analyzed using Peaks Studio version 10.6 (Bioinformatics Solution Inc.), searching against the C. elegans protein sequence database from Swiss-Prot (4155 entries). The maximum number of variable modifications detected on a peptide was restricted to three, allowing the following variable modifications: methionine oxidation, cysteine propionamidation, methylation of lysine (mono, di, and tri), and methylation of the N-terminus (mono, di, and tri). MS/MS spectra of peptides containing the N-terminal G2 or K55 of EEF-1A were inspected for presence of methylated residues, followed by quantitation of G2 and K55 methylation status using PEAKS Studio. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD042540 and 10.6019/PXD042540 [50].

Western blot analysis

Pellets containing a mix of embryos, larvae and adults were prepared as described above. Lysates were prepared by grinding the pellet with a mortar and pestle in the presence of liquid nitrogen and dissolving in lysis buffer (50 mM HEPES (pH 7.4), 150 mM KCl, 5 mM MgCl2, 0.1% Triton X-100, 5% glycerol (w/vol), 1 mM PMSF, 7 mg/ml cOmplete Proteinase Inhibitor Tablets (Roche, 11697498001). Lysates were cleared by centrifugation at 16100 x g for 20 minutes at 4°C. Protein concentrations were approximated by Bradford Assay (Bio-Rad). Samples were prepared by mixing 25 micrograms of protein extract with the required amount of 4x NuPAGE™ LDS Sample Buffer (Invitrogen, NP0007) and 10x NuPAGE Sample Reducing Agent (Invitrogen, NP0004), followed by heating at 70°C for 10 minutes. Proteins were separated by SDS-PAGE and transferred onto a polyvinylidene difluoride membrane by wet-transfer. The following primary antibodies were used: 1:1000 monoclonal mouse anti-eEF1A (Merck, 05–235), 1:10000 monoclonal mouse anti-puromycin (Merck, MABE343), 1:5000 polyclonal rabbit anti-actin (Abcam, ab8227). Detection was carried out with IRDye 680RD-conjugated goat anti-mouse secondary antibody (LI-COR Biosciences, 926–68070) or IRDye 800CW-conjugated goat anti-rabbit secondary antibody (LI-COR Biosciences, 926–32211) and infrared imaging (LI-COR Biosciences, Odyssey CLx).

SUnSET assay

Synchronous arrested L1 larvae were obtained as described above. A total of 16000 L1 larvae were grown until the young adult stage on NGM plates seeded with E. coli OP50 bacteria. Animals were washed, grown and treated with puromycin as previously described [29]. For the Western blot analysis, three micrograms of total protein were used per well. Incorporation of puromycin into nascent peptides was measured by normalizing band intensity from monoclonal anti-puromycin (Merck, MABE343) antibody to anti-actin (Abcam, ab8227).

Microscopy

Animals were transferred into a drop of 10 mM levamisole on a 2% (w/v) agarose pad, covered with a cover slip and immediately imaged with a Zeiss AxioImager Z1 microscope. Images were acquired with an Axiocam MRm REV2 CCD camera using the Zen software (Zeiss). The acquired images were processed with Image J.

Development and fecundity assay

Synchronized arrested L1 larvae were plated on NGM agar plates with OP50 and grown at 25°C for 24 hours to the L4 larval stage. Individual animals were picked over so that there is one single worm per NGM agar plate. The animals and their offspring were left to grow at 25°C, 20°C, or 15°C. The parental animal was picked over to a new plate every 24 hours and the offspring was counted and removed from the plate when they reached the L4 stage.

Body area measurements

Synchronous arrested L1 larvae were obtained as described above. A minimum of 50 animals were grown at 25°C until 1-day old adults on NGM plates seeded with either E. coli OP50 or HB101 bacteria. Micrographs depicting the whole animal were taken of a minimum of 15 worms for each strain and each food-source condition per biological replicate. Body area of the animals in square pixels was measured with Image J.

Egg-to-egg assay

Four adult animals were picked on an NGM plate seeded with either E. coli OP50 or E. coli HB101 bacteria to lay eggs at 25°C for 2 hours before being removed. The eggs were grown at 25°C into the L4 stage before separating a single worm per plate for a total of 20 worms for each strain and food-source condition per biological replicate. The animals were kept at 25°C and checked every hour after entering adulthood to mark the time at which they start laying their first egg.

Lifespan assay

Synchronous arrested L1 larvae were obtained as described above. A minimum of 100 L1 larvae were plated out per NGM agar plate and left to grow until the young adult stage at 20°C. Dead animals were counted and removed from the plate every 48 hours. The population of animals was moved to a new plate every 24 hours during fertile adulthood to omit the offspring from the assay.

Supporting information

S1 File. Contains all the supporting figures.

(DOCX)

S1 Raw images

(PDF)

Data Availability

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD042540 and 10.6019/PXD042540. All other data are within the manuscript and its Supporting Information files.

Funding Statement

This work was supported by the Research Council of Norway grant FRIMEDBIO-286499 to RC, and by the Norwegian Cancer Society's grants 228890 to RC and 207855 to PF. The research leading to these results also received funding from the Norwegian Financial Mechanism 2014–2021 operated by the Polish National Science Center under the project contract nr UMO-2019/34/H/NZ3/00691. Some of the strains were provided by the Caenorhabditis Genetics Center (CGC), funded by the NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Schubert HL, Blumenthal RM, Cheng X. Many paths to methyltransfer: A chronicle of convergence. Trends Biochem Sci. 2003;28: 329–335. doi: 10.1016/S0968-0004(03)00090-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Petrossian TC, Clarke SG. Uncovering the human methyltransferasome. Mol Cell Proteomics. 2011;10: 1–12. doi: 10.1074/mcp.M110.000976 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Clarke SG. Protein methylation at the surface and buried deep: Thinking outside the histone box. Trends Biochem Sci. 2013;38: 243–252. doi: 10.1016/j.tibs.2013.02.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Falnes P, Jakobsson ME, Davydova E, Ho A, Małecki J. Protein lysine methylation by seven-β-strand methyltransferases. Biochem J. 2016;473: 1995–2009. doi: 10.1042/BCJ20160117 [DOI] [PubMed] [Google Scholar]
  • 5.Webb KJ, Zurita-Lopez CI, Al-Hadid Q, Laganowsky A, Young BD, Lipson RS, et al. A novel 3-methylhistidine modification of yeast ribosomal protein Rpl3 is dependent upon the YIL110W methyltransferase. J Biol Chem. 2010;285: 37598–37606. doi: 10.1074/jbc.M110.170787 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Kwiatkowski S, Seliga AK, Vertommen D, Terreri M, Ishikawa T, Grabowska I, et al. SETD3 protein is the actin-specific histidine N-methyltransferase. Elife. 2018;7: 1–42. doi: 10.7554/eLife.37921 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Figaro S, Scrima N, Buckingham RH, Heurgué-Hamard V. HemK2 protein, encoded on human chromosome 21, methylates translation termination factor eRF1. FEBS Lett. 2008;582: 2352–2356. doi: 10.1016/j.febslet.2008.05.045 [DOI] [PubMed] [Google Scholar]
  • 8.Passos DO, Quaresma AJC, Kobarg J. The methylation of the C-terminal region of hnRNPQ (NSAP1) is important for its nuclear localization. Biochem Biophys Res Commun. 2006;346: 517–525. doi: 10.1016/j.bbrc.2006.05.152 [DOI] [PubMed] [Google Scholar]
  • 9.Cornett EM, Ferry L, Defossez PA, Rothbart SB. Lysine Methylation Regulators Moonlighting outside the Epigenome. Mol Cell. 2019;75: 1092–1101. doi: 10.1016/j.molcel.2019.08.026 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Davydova E, Shimazu T, Schuhmacher MK, Jakobsson ME, Willemen HLDM, Liu T et al. The methyltransferase METTL9 mediates pervasive 1-methylhistidine modification in mammalian proteomes. Nat Commun. 2021;1 2. doi: 10.1038/s41467-020-20670-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Diaz K, Meng Y, Huang R. Past, present, and perspectives of protein N-terminal methylation. Curr Opin Chem Biol. 2021;63: 115–122. doi: 10.1016/j.cbpa.2021.02.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Wu Q, Schapira M, Arrowsmith CH, Barsyte-Lovejoy D. Protein arginine methylation: from enigmatic functions to therapeutic targeting. Nat Rev Drug Discov. 2021;20: 509–530. doi: 10.1038/s41573-021-00159-8 [DOI] [PubMed] [Google Scholar]
  • 13.Dever TE, Green R. The elongation, termination, and recycling phases of translation in eukaryotes. Cold Spring Harb Perspect Biol. 2012;4: 1–16. doi: 10.1101/cshperspect.a013706 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Peters HI, Chang YE, Traugh JA. Phosphorylation of Elongation Factor 1 (EF‐1) by Protein Kinase C Stimulates GDP/GTP‐Exchange Activity. Eur J Biochem. 1995;234: 550–556. doi: 10.1111/j.1432-1033.1995.550_b.x [DOI] [PubMed] [Google Scholar]
  • 15.Eckhardt K, Tröger J, Reissmann J, Katschinski DM, Wagner KF, Stengel P, et al. Male germ cell expression of the PAS domain kinase PASKIN and its novel target eukaryotic translation elongation factor eEF1A1. Cell Physiol Biochem. 2007;20: 227–240. doi: 10.1159/000104169 [DOI] [PubMed] [Google Scholar]
  • 16.Lin KW, Yakymovych I, Jia M, Yakymovych M, Souchelnytskyi S. Phosphorylation of eEF1A1 at Ser300 by TβR-I results in inhibition of mRNA translation. Curr Biol. 2010;20: 1615–1625. doi: 10.1016/j.cub.2010.08.017 [DOI] [PubMed] [Google Scholar]
  • 17.Chang YWE, Traugh JA. Insulin stimulation of phosphorylation of elongation factor 1 (eEF-1) enhances elongation activity. Eur J Biochem. 1998;251: 201–207. doi: 10.1046/j.1432-1327.1998.2510201.x [DOI] [PubMed] [Google Scholar]
  • 18.Hamey JJ, Wilkins MR. Methylation of Elongation Factor 1A: Where, Who, and Why? Trends Biochem Sci. 2018;43: 211–223. doi: 10.1016/j.tibs.2018.01.004 [DOI] [PubMed] [Google Scholar]
  • 19.Jakobsson ME, Małecki J, Nilges BS, Moen A, Leidel SA, Falnes P. Methylation of human eukaryotic elongation factor alpha (eEF1A) by a member of a novel protein lysine methyltransferase family modulates mRNA translation. Nucleic Acids Res. 2017;45: 8239–8254. doi: 10.1093/nar/gkx432 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Hamey JJ, Winter DL, Yagoub D, Overall CM, Hart-Smith G, Wilkins MR. Novel N-terminal and lysine methyltransferases that target translation elongation factor 1A in yeast and human. Mol Cell Proteomics. 2016;15: 164–176. doi: 10.1074/mcp.M115.052449 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Małecki J, Aileni VK, Ho AYY, Schwarz J, Moen A, Sørensen V, et al. The novel lysine specific methyltransferase METTL21B affects mRNA translation through inducible and dynamic methylation of Lys-165 in human eukaryotic elongation factor 1 alpha (eEF1A). Nucleic Acids Res. 2017;45: 4370–4389. doi: 10.1093/nar/gkx002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Shimazu T, Barjau J, Sohtome Y, Sodeoka M, Shinkai Y. Selenium-based S-adenosylmethionine analog reveals the mammalian seven-beta-strand methyltransferase METTL10 to be an EF1A1 lysine methyltransferase. PLoS One. 2014;9. doi: 10.1371/journal.pone.0105394 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Hamey JJ, Wienert B, Quinlan KGR, Wilkins MR. METTL21B Is a Novel Human lysine methyltransferase of translation elongation factor 1A: Discovery by CRISPR/Cas9 Knockout. Mol Cell Proteomics. 2017;16: 2229–2242. doi: 10.1074/mcp.M116.066308 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Jakobsson ME, Małecki JM, Halabelian L, Nilges BS, Pinto R, Kudithipudi S, et al. The dual methyltransferase METTL13 targets N terminus and Lys55 of eEF1A and modulates codon-specific translation rates. Nat Commun. 2018;9: 3411. doi: 10.1038/s41467-018-05646-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Liu S, Hausmann S, Carlson SM, Fuentes ME, Francis JW, Pillai R, et al. METTL13 Methylation of eEF1A Increases Translational Output to Promote Tumorigenesis. Cell. 2019;176: 491–504.e21. doi: 10.1016/j.cell.2018.11.038 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Wang X, Li K, Wan Y, Chen F, Cheng M, Xiong G, et al. Methyltransferase like 13 mediates the translation of Snail in head and neck squamous cell carcinoma. Int J Oral Sci. 2021;13: 1–11. doi: 10.1038/s41368-021-00130-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Li L, Zheng YL, Jiang C, Fang S, Zeng TT, Zhu YH, et al. HN1L-mediated transcriptional axis AP-2γ/METTL13/TCF3-ZEB1 drives tumor growth and metastasis in hepatocellular carcinoma. Cell Death Differ. 2019;26: 2268–2283. doi: 10.1038/s41418-019-0301-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Takahashi A, Tokita H, Takahashi K, Takeoka T, Murayama K, Tomotsune D, et al. A novel potent tumour promoter aberrantly overexpressed in most human cancers. Sci Rep. 2011;1: 5–9. doi: 10.1038/srep00015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Arnold A, Rahman MM, Lee MC, Muehlhaeusser S, Katic I, Gaidatzis D, et al. Functional characterization of C. elegans Y-box-binding proteins reveals tissue-specific functions and a critical role in the formation of polysomes. Nucleic Acids Res. 2014;42: 13353–13369. doi: 10.1093/nar/gku1077 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Schmidt EK, Clavarino G, Ceppi M, Pierre P. SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods. 2009;6: 275–277. doi: 10.1038/nmeth.1314 [DOI] [PubMed] [Google Scholar]
  • 31.Vanden Broek K, Han X, Hansen D. Redundant mechanisms regulating the proliferation vs. differentiation balance in the C. elegans germline. Front Cell Dev Biol. 2022;10: 1–15. doi: 10.3389/fcell.2022.960999 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Jones AR, Schedl T. Mutations in gld-1, a female germ cell-specific tumor suppressor gene in Caenorhabditis elegans, affect a conserved domain also found in Src- associated protein Sam68. Genes Dev. 1995;9: 1491–1504. doi: 10.1101/gad.9.12.1491 [DOI] [PubMed] [Google Scholar]
  • 33.Lee MH, Schedl T. Identification of in vivo mRNA targets of GLD-1, a maxi-KH motif containing protein required for C. elegans germ cell development. Genes Dev. 2001;15: 2408–2420. doi: 10.1101/gad.915901 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Biedermann B, Wright J, Senften M, Kalchhauser I, Sarathy G, Lee MH, et al. Translational Repression of Cyclin E Prevents Precocious Mitosis and Embryonic Gene Activation during C. elegans Meiosis. Dev Cell. 2009;17: 355–364. doi: 10.1016/j.devcel.2009.08.003 [DOI] [PubMed] [Google Scholar]
  • 35.Scheckel C, Gaidatzis D, Wright JE, Ciosk R. Genome-wide analysis of GLD-1-mediated mRNA regulation suggests a role in mRNA storage. PLoS Genet. 2012;8: 1–12. doi: 10.1371/journal.pgen.1002742 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Voutev R, Killian DJ, Hyungsoo Ahn J, Hubbard EJA. Alterations in ribosome biogenesis cause specific defects in C. eleganshermaphrodite gonadogenesis. Dev Biol. 2006;298: 45–58. doi: 10.1016/j.ydbio.2006.06.011 [DOI] [PubMed] [Google Scholar]
  • 37.Byerly L, Cassada RC, Russell RL. The life cycle of the nematode Caenorhabditis elegans. Dev Biol. 1976;51: 23–33. doi: 10.1016/0012-1606(76)90119-6 [DOI] [PubMed] [Google Scholar]
  • 38.Avery L, Shtonda BB. Food transport in the C. elegans pharynx. J Exp Biol. 2003;206: 2441–2457. doi: 10.1242/jeb.00433 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Soukas AA, Kane EA, Carr CE, Melo JA, Ruvkun G. Rictor/TORC2 regulates fat metabolism, feeding, growth, and life span in Caenorhabditis elegans. Genes Dev. 2009;16: 639–651. doi: 10.1101/gad.1775409 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.So S, Miyahara K, Ohshima Y. Control of body size in C. elegans dependent on food and insulin/IGF-1 signal. Genes to Cells. 2011;16: 639–651. doi: 10.1111/j.1365-2443.2011.01514.x [DOI] [PubMed] [Google Scholar]
  • 41.Brenner S. The genetics of Caenorhabditis elegans. Genetics. 1974;77: 71–94. doi: 10.1093/genetics/77.1.71 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Slobin L. The role of eucaryotic elongation factor Tu in protein synthesis. Eur J Biochem. 1980;563: 555–563. Available: http://onlinelibrary.wiley.com/doi/ doi: 10.1111/j.1432-1033.1980.tb04898.x/full [DOI] [PubMed] [Google Scholar]
  • 43.Rubio A, Garland GD, Sfakianos A, Harvey RF, Willis AE. Aberrant protein synthesis and cancer development: The role of canonical eukaryotic initiation, elongation and termination factors in tumorigenesis. Semin Cancer Biol. 2022. doi: 10.1016/j.semcancer.2022.04.006 [DOI] [PubMed] [Google Scholar]
  • 44.Truitt ML, Conn CS, Shi Z, Pang X, Tokuyasu T, Coady AM, et al. Differential Requirements for eIF4E Dose in Normal Development and Cancer. Cell. 2015;162: 59–71. doi: 10.1016/j.cell.2015.05.049 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Zou Z, Tao T, Li H, Zhu X. MTOR signaling pathway and mTOR inhibitors in cancer: Progress and challenges. Cell Biosci. 2020;10: 1–11. doi: 10.1186/s13578-020-00396-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Tao Z, Li T, Ma H, Yang Y, Zhang C, Hai L, et al. Autophagy suppresses self-renewal ability and tumorigenicity of glioma-initiating cells and promotes Notch1 degradation. Cell Death Dis. 2018;9. doi: 10.1038/s41419-018-0957-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Laham-Karam N, Pinto GP, Poso A, Kokkonen P. Transcription and Translation Inhibitors in Cancer Treatment. Front Chem. 2020;8: 1–24. doi: 10.3389/fchem.2020.00276 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Ahringer J. Reverse genetics. WormBook: the online review of C elegans biology. 2006. pp. 1–43. [Google Scholar]
  • 49.Małecki JM, Odonohue MF, Kim Y, Jakobsson ME, Gessa L, Pinto R, et al. Human METTL18 is a histidine-specific methyltransferase that targets RPL3 and affects ribosome biogenesis and function. Nucleic Acids Res. 2021;49: 3185–3203. doi: 10.1093/nar/gkab088 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Perez-Riverol Y, Bai J, Bandla C, García-Seisdedos D, Hewapathirana S, Kamatchinathan S, et al. The PRIDE database resources in 2022: A hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 2022;50: D543–D552. doi: 10.1093/nar/gkab1038 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Alexander F Palazzo

28 Apr 2023

PONE-D-23-07410Characterization of the biochemical activity and tumor-promoting role of the dual protein methyltransferase METL-13/METTL13 in Caenorhabditis elegans.PLOS ONE

Dear Dr. Ciosk,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. The only additional experiment that needs to be performed, is to repeat the experiment in Figure 4B with the expression of wildtype proteins to rule out that the phenotypes observed are due to undetected background mutations. Other changes that are requested by the reviewers can be addressed by modifying the figures and text.

Please submit your revised manuscript by Jun 12 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Alexander F. Palazzo, Ph.D.

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

3. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

4. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

5. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors describe the in vivo relevance of an uncharacterized methyltransferase family member METTL13 using C. elegans as the model. METTL13 in humans is shown to methylate two sites on the translation elongation factor, but its in vivo relevance in an organismic model is not known. Here they demonstrate the biochemical activity of worm METTL13, show that it is dispensable in vivo, but show that germline tumors depend on it for full penetrance. This is a highly relevant finding, given that human protein and methylation of the translation elongation factor is linked to tumors. This raises the possibility that genetic replacement of the worm protein with the human orthologue may allow creation of a genetic model system for screening small molecule inhibitors. I find this study to be very interesting and support its publication.

Minor:

Some of the references linked to protein methyltransferases could include the more recent ones.

Please mention what the other modifications on the elongation factor does for its in vivo functions.

A clearer description of the tumor phenotype (fully proliferative vs fully proliferative with enlarged cells) will be useful.

Reviewer #2: In the manuscript by Engelfriet et al, the authors use C. elegans as a model to study the methyltransferase METL-13 and its methylation of EEF-1A (homologues of the human METTL13 and eEF1A respectively). METTL13 and the methylation of eEF1A have been previously shown to promote carcinogenesis in cell culture, but an in vivo/whole animal study has not been conducted yet.

First the authors show that the enzymatic activity of the two METL-13 MTase domains is the same between humans and worms by using the worm MTAse domains to methylate recombinant human eEF1A. eEF1A is methylated at the same positions by the worm MTases showing strong functional homology even though the sequences diverged over the course of evolution, which strengthens the author’s point of C. elegans being able to serve as an appropriate model for the role in human cancer. The authors show that the in vivo methylation of EEF-1A at positions G2 and K55 is solely dependent on the presence of METL-13 by looking at the methylation pattern in a metl-13 mutant. The authors further investigate the role of METL-13 and methylation of EEF-1A in two germline tumor contexts. Both the metl-13 mutant and a double-mutant eef-1A strain (which lacks the K55 methylation sites) show a decreased severity of tumors in a gld-1 knockdown, and a knockdown of metl-13 shows a lowered tumor burden in a temperature sensitive pro-1 mutant. The authors note that absence of METL-13 or the methylation sites in EEF-1A does not fully prevent tumorigenesis, but still reduces tumor burden in both contexts. In order to show that an absence of METL-13 is not detrimental to the fitness of worms (and thereby a potentially good target for therapeutics), the authors performed experiments showing that fertility and development of worms is not affected in a metl-13 mutant strain.

With this study the authors show that C. elegans can serve as a model to further study METTL13’s role in carcinogenesis and development of potential treatment options based on targeting of METTL13. The manuscript is overall well written, easy to follow, and the conclusions drawn by the authors are supported by the presented experiments and results. Although I already consider this an excellent manuscript, I have a few points that should be addressed before being accepted for publication to bolster the author’s conclusions, which I will detail below.

Major points:

Experiment presented in Fig. 4B: In order to fully support the conclusion that a mutation in either metl-13 or the K55 methylation sites of eef-1A are responsible for the decreased severity of the tumors, it would be necessary to reconstitute the mutants by expressing the wildtype proteins. By showing that addition of the wildtype proteins restores the wildtype phenotype, the authors can strengthen their conclusions (and exclude undetected background mutations).

Fig 4B/C: The authors should also include the sample size of observations on which the bar graphs are based on. Furthermore, the authors should strongly consider showing example images from gld-1 RNAi treated mutant worms and pro-1(na48) worms after metl-13 RNAi to allow the reader to assess the tumors in these contexts.

Fig. 4A: Recolor the tumorous cells to have a different color from the early germline cells and reference this color code in the legend or figure itself.

General:

The manuscript is lacking details/methods on the generation of the eef-1A mutant strains.

Can the authors add a section in the discussion to detail in what way the Ce germline tumors are known to be similar or different to the human tumors in which METTL-13 has been shown to be relevant? This would allow the reader to more thoroughly assess how transferable knowledge from the worm model is to human cancer biology.

The authors should deposit the data of their MS experiments in a public repository to allow for analysis by the community.

Minor points:

Fig. 5: Add the number of worms that have been used to the figure legend (in addition to the mention in the methods)

Fig. S1A: I would suggest adding a consensus sequence highlighting the common and different amino acids below the shown human and Ce sequences.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Jun 22;18(6):e0287558. doi: 10.1371/journal.pone.0287558.r002

Author response to Decision Letter 0


2 Jun 2023

We appreciate the reviewers’ comments on the manuscript. Below is our point-by-point response to their concerns.

Reviewer #1:

Minor:

Some of the references linked to protein methyltransferases could include the more recent ones.

We have included four more recent references to give a better overview of the extent of protein methylation on different types of residues (Cornett et al., Molecular Cell, 2019; Wu et al., Nature Reviews Drug Discovery, 2021; Diaz et al., Current Opinion in Chemical Biology, 2021; Davydova et al., Nature Communications, 2021). The references are linked to the following sentence in the introduction: “Methylation occurs most often on lysines and arginines, but other residues, such as histidines and the N- and C-termini of proteins, are also methylated.”. The more recent review on protein lysine methylation outside of histones (Cornett et al., Molecular Cell, 2019) has also been added as a reference to the following sentence in the introduction: “Although lysine methylation of histone proteins has received much attention, many lysine-specific MTases (KMTs) methylate non-histone proteins.”.

Please mention what the other modifications on the elongation factor does for its in vivo functions.

The introduction section now includes a general description of the effects of phosphorylation and methylation on the canonical function of eEF1A in translation elongation. We hope the Reviewer will agree that further elaborations on different types of PTMs and their effects on canonical and non-canonical functions of eEF1A are outside the scope of this paper.

A clearer description of the tumor phenotype (fully proliferative vs fully proliferative with enlarged cells) will be useful.

We have added the following statement in the Results section, discussing the tumorous phenotype upon knockdown of gld-1: “Upon depletion of GLD-1, germ cells that have entered meiosis revert to the mitotic cycle, resulting in an ectopic mass of proliferative cells that we refer to as a ‘fully proliferative’ phenotype.”. We have also modified the text in the same paragraph, describing the ‘proliferative with enlarged cells’ phenotype seen in the metl-13(tm6870) and eef-1A.1(syb2837); eef-1A.2(syb2785) mutant animals.

Reviewer #2:

Major points:

Experiment presented in Fig. 4B: In order to fully support the conclusion that a mutation in either metl-13 or the K55 methylation sites of eef-1A are responsible for the decreased severity of the tumors, it would be necessary to reconstitute the mutants by expressing the wildtype proteins. By showing that addition of the wildtype proteins restores the wildtype phenotype, the authors can strengthen their conclusions (and exclude undetected background mutations).

We understand that such rescuing experiments are common in many fields. However, they are non-trivial and time-consuming to perform in C. elegans. We would either need to revert the mutant strains back to wild-type by CRISPR-Cas9 genome editing or express full-length rescue constructs, including uncharacterized endogenous promoters and 3’UTRs. In the latter case, we would need to insert ectopic copies into a different locus, which also could impact expression. We understand the concern that off-target mutations in the CRISPR-Cas9 edited mutant strains could play a role in the severity of the observed tumor phenotypes. However, we think that undetected background mutations are unlikely to play a role. In this model, it is customary to outcross CRISPR-Cas9 edited strains several times (usually three times) against the wild type to exclude off-target mutations. Indeed, it was done for all mutant strains generated in this study. This is now described in the Methods section (C. elegans culture and generation of mutant strains). We acknowledge that an off-target mutation could occur close to the edited locus and remain in the strain despite outcrossing. However, we find it highly unlikely that two random off-target mutations (one linked to the metl-13 locus and the other to either the eef-1A.1 or eef-1A.2 locus) would cause identical phenotypes, i.e. the suppression of the gld-1 tumor. Thus, we find it justified to conclude that the phenotype is caused by mutations in met-13 or eef-1A.1; eef-1A.2, rather than background mutations. Finally, our observations on the role of METL-13 in C. elegans are in line with the findings reported in mice on METTL13. Considering all that, we hope that the Reviewer will agree that additional control experiments are unnecessary.

Fig 4B/C: The authors should also include the sample size of observations on which the bar graphs are based on. Furthermore, the authors should strongly consider showing example images from gld-1 RNAi treated mutant worms and pro-1(na48) worms after metl-13 RNAi to allow the reader to assess the tumors in these contexts.

The number of germlines that were assessed for each biological replicate is now added to the legend of Figures 4B and 4C. Example images of metl-13(tm6870) and eef-1A.1(syb2837); eef-1A.2(syb2785) mutant animals after gld-1 RNAi are now shown in Supplementary Figure 2A, example images of pro-1(na48) mutant animals after metl-13 RNAi are shown in Supplementary Figure 2B.

Fig. 4A: Recolor the tumorous cells to have a different color from the early germline cells and reference this color code in the legend or figure itself.

The tumorous cells in the schematic of Figure 4A have been recolored red, which is now also mentioned in the legend of Figure 4A.

General:

The manuscript is lacking details/methods on the generation of the eef-1A mutant strains.

The single-mutant strains eef-1A.1(syb2837) and eef-1A.2(syb2785) were generated by SunyBiotech using CRISPR/Cas9 genome editing, after which we outcrossed the single-mutants thrice to wild-type N2 animals. After this, the single-mutants were crossed to generate the double-mutant strain eef-1A.1(syb2837); eef-1A.2(syb2785) which was again outcrossed thrice. This is now better explained in the Methods section describing the generation of mutant strains.

Can the authors add a section in the discussion to detail in what way the Ce germline tumors are known to be similar or different to the human tumors in which METTL-13 has been shown to be relevant? This would allow the reader to more thoroughly assess how transferable knowledge from the worm model is to human cancer biology.

We have now included the following text in the Discussion section: While the etiology of human and C. elegans tumors is likely different, it is intriguing that mutating various C. elegans RNA-binding proteins, which like GLD-1 function to repress translation, leads to germline tumors (Vanden Broek et al., Frontiers in Cell and Developmental Biology, 2022). Thus, reducing translational output, by removing METL-13, could explain the partial suppression of the tumorous proliferation observed upon the depletion of GLD-1. Whether the same applies to pro-1 tumors is less clear, as their etiology is less well understood (Voutev et al., Developmental Biology, 2006).

The authors should deposit the data of their MS experiments in a public repository to allow for analysis by the community.

The MS proteomics data on the methylation status of G2 and K55 in wild-type and metl-13(tm6870) animals has now been deposited to the ProteomeXchange Consortium via the PRIDE partner repository. The dataset identifiers are now described in the text in the Methods section.

Minor points:

Fig. 5: Add the number of worms that have been used to the figure legend (in addition to the mention in the methods).

We have now added the number of worms used for the body area measurements and the egg-to-egg assays in the legend of Figures 5C and 5D.

Fig. S1A: I would suggest adding a consensus sequence highlighting the common and different amino acids below the shown human and Ce sequences.

Rather than introducing a consensus sequence, we have modified Supplementary Figure S1A by introducing an orange text color to highlight differences in amino acid sequence between the human and C. elegans eEF1A/EEF-1A.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Alexander F Palazzo

7 Jun 2023

Characterization of the biochemical activity and tumor-promoting role of the dual protein methyltransferase METL-13/METTL13 in Caenorhabditis elegans.

PONE-D-23-07410R1

Dear Dr. Ciosk,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Alexander F. Palazzo, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Alexander F Palazzo

13 Jun 2023

PONE-D-23-07410R1

Characterization of the biochemical activity and tumor-promoting role of the dual protein methyltransferase METL-13/METTL13 in Caenorhabditis elegans.

Dear Dr. Ciosk:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Alexander F. Palazzo

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Contains all the supporting figures.

    (DOCX)

    S1 Raw images

    (PDF)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD042540 and 10.6019/PXD042540. All other data are within the manuscript and its Supporting Information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES